Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors-letter

摘要

There is much effort to develop new therapeutic approaches to rescue dysfunctional T cells in patients with cancer. In the June issue of Cancer Research, Duraiswamy and colleagues demonstrate that a triple therapy consisting of anti-PD-1, anti-CTLA-4, and therapeutic vaccination provides consistent rejection of experimental tumors (1). This triple therapy was better than any single- or double-agent combination.